Literature DB >> 11316121

Effect of low-intensity warfarin therapy on left atrial thrombus resolution in patients with nonvalvular atrial fibrillation: a transesophageal echocardiographic study.

M Kimura1, Y Wasaki, H Ogawa, M Nakatsuka, T Wakeyama, T Iwami, K Ono, F Nakao, M Matsuzaki.   

Abstract

The presence of left atrial thrombus (LAT) is associated with an increased risk of embolic stroke. However, it has yet to be established definitively whether low-intensity warfarin therapy (INR: 1.5-2.0) can prevent LAT formation in patients with nonvalvular atrial fibrillation (NVAF). The present study analyzed the clinical and transesophageal echocardiography (TEE) features of 123 such patients to identify risk factors for LAT formation and the efficacy of prophylactic low-intensity warfarin therapy. Left atrial thrombi were found in 35 patients (28%) in whom systemic hypertension (49% vs 23%; p<0.01) and ischemic heart disease (17% vs 3%; p<0.01) were more frequent. Left ventricular ejection fraction (54+/-14% vs 60+/-11%; p<0.05), left ventricular end-diastolic dimension (51+/-7 mm vs 48+/-5 mm; p<0.05), spontaneous echo contrast (2.2+/-0.7 vs 1.4+/-0.9; p<0.01), left atrial diameter (50+/-6 mm vs 43+/-7 mm; p<0.01), left atrial appendage blood velocity (22.3+/-8.7 cm/s vs 37.2+/-21.5 cm/s; p<0.01) and the incidence of left ventricular hypertrophy (37% vs 15%; p<0.01) were also significantly different between the groups. Fourteen patients received continuous warfarin therapy (target INR: 1.5-2.0) and on the follow-up TEE study the left atrial thrombus resolved in 10 (71%). There were no thromboembolic events or major hemorrhagic complications in these patients, so it was concluded that low-intensity warfarin therapy is efficacious in treating LAT formation in patients with NVAF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316121     DOI: 10.1253/jcj.65.271

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  8 in total

1.  Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient.

Authors:  Gloria Santangelo; Alfonso Ielasi; Pasquale Antonio Scopelliti; Francesco Pattarino; Maurizio Tespili
Journal:  J Atr Fibrillation       Date:  2016-12-31

2.  Prediction of left atrial thrombi in patients with atrial tachyarrhythmias during warfarin administration: retrospective study in Hyogo College of Medicine.

Authors:  Hideyuki Kishima; Takanao Mine; Takeshi Kodani; Tohru Masuyama
Journal:  Heart Vessels       Date:  2015-05       Impact factor: 2.037

Review 3.  The Optimal Treatment For Atrial Fibrillation In Less Developed Countries.

Authors:  Xiaohan Fan; Shu Zhang
Journal:  J Atr Fibrillation       Date:  2014-10-31

4.  Resolution of left atrial appendage thrombus with apixaban.

Authors:  Tohru Kawakami; Hiroko Kobayakawa; Hiroyoshi Ohno; Nobukiyo Tanaka; Hiroki Ishihara
Journal:  Thromb J       Date:  2013-12-20

5.  Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.

Authors:  Paolo Verdecchia; Gianpaolo Reboldi; Fabio Angeli; Giovanni Mazzotta; Gregory Y H Lip; Martina Brueckmann; Eva Kleine; Lars Wallentin; Michael D Ezekowitz; Salim Yusuf; Stuart J Connolly; Giuseppe Di Pasquale
Journal:  Europace       Date:  2018-02-01       Impact factor: 5.214

6.  Editorial: Resolution of left atrial thrombus with novel oral anticoagulants.

Authors:  Satoshi Fujii
Journal:  J Cardiol Cases       Date:  2014-10-08

7.  Warfarin maintenance dose Prediction for Patients undergoing heart valve replacement- a hybrid model with genetic algorithm and Back-Propagation neural network.

Authors:  Qian Li; Huan Tao; Jing Wang; Qin Zhou; Jie Chen; Wen Zhe Qin; Li Dong; Bo Fu; Jiang Long Hou; Jin Chen; Wei-Hong Zhang
Journal:  Sci Rep       Date:  2018-06-26       Impact factor: 4.379

8.  Dabigatran Therapy Resulting in the Resolution of Rivaroxaban-resistant Left Atrial Appendage Thrombi in Patients with Atrial Fibrillation.

Authors:  Tetsuya Watanabe; Yukinori Shinoda; Kuniyasu Ikeoka; Tomoko Minamisaka; Hidetada Fukuoka; Hirooki Inui; Shiro Hoshida
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.